LOWER

STUDY IDENTIFIER:

LOWER

CONDITION:

Homozygous Familial Hypercholesterolemia

CONTACT INFO:

Christine Majeski   |   Christine.Majeski@allina.com   |   612-863-3546

DESCRIPTION:

This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.

CRITERIA LIST/ QUALIFICATIONS:

  • Initiating treatment with lomitapide at the time of registry enrolment, or initiated treatment with lomitapide within 15 months prior to enrolment into the registry and after lomitapide commercial availability in the country.
  • Patients who have the ability to understand the requirements of the study and provide written informed consent to comply with the study data collection procedures.

INVESTIGATORS:

Thomas Knickelbine, MD

SPONSORS:

Aegerion Pharmaceuticals, Inc.

STATUS:

Open/Enrolling

Support the research and educational efforts of MHIF

Make a Donation